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ha
MaSeveral monogenic cardiac disorders are associated with sudden cardiac death. These include primary electrophysio-
logical disorders (long QT, short QT, Brugada, and catecholaminergic ventricular tachycardia syndromes) and cardio-
myopathies, including hypertrophic and dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.
This review presents the genotype–phenotype relations in these diseases. In addition to establishing a diagnosis, imaging
can play an important role in identifying the pathophysiological abnormalities and hence the potential to guide therapy in
some patients. Furthermore, imaging ﬁndings in some patients add incremental prognostic information for risk stratiﬁ-
cation of sudden cardiac death. Finally, along with genetic testing, imaging is important for screening and, in some cases,
can identify subjects with positive mutations who have not yet developed the classical phenotype. (J Am Coll Cardiol Img
2015;8:828–45) © 2015 by the American College of Cardiology Foundation.T he annual incidence of sudden cardiacdeath (SCD) in the United States exceeds300,000 cases per year (1). In athletes, it
has an incidence of 1:80,000 to 1:40,000, although
it seems to occur more frequently in African-
American athletes (2). There are known risk factors
such as diabetes mellitus, hyperlipidemia, smoking
in patients with coronary artery disease, and left
ventricular hypertrophy (LVH). A number of pa-
tients with SCD have a predisposition that is genet-
ically determined and which interacts with
environmental factors. There are also diseases that
are primarily monogenic in inheritance and can
lead to SCD. These include myocardial diseases
(10% to 15% of cases of SCD), primary electrophysi-
ological (EP) problems (5% of cases), and rare
vascular disorders. The present review addresses
the implications for imaging with respect to the
genotype–phenotype relations in these monogenic
disorders (1).m the Cardiovascular Imaging Institute, Houston Methodist DeBakey Hea
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Long QT syndrome (LQTS), Brugada syndrome, short
QT syndrome, and catecholaminergic ventricular
tachycardia all cause SCD. Although EP abnormalities
are readily recognized as important ﬁndings in these
diseases, abnormalities in cardiac function have more
recently been reported in some patients with LQTS.
LQTS is caused by mutations in proteins that encode
the sodium and potassium ion channels. Some syn-
dromes have an autosomal dominant inheritance; it is
autosomal recessive in others, as in the Jervell and
Lange-Nielsen syndrome in which deafness occurs
alongwith SCD. LQTS1 and LQTS2 are due to potassium
channel mutations, and LQTS3 is due to sodium
channel mutations. In LQTS, action potential duration
is prolonged due to delayed repolarization, which is
associated with early afterdepolarizations and with
electrical dispersion. Predictors of cardiac events in
this patient population include LQTS locus, sex, andrt and Vascular Center, Houston, Texas. The authors
is paper to disclose.
8, 2015, accepted April 23, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
ARVC = arrhythmogenic right
ventricular cardiomyopathy
CMR = cardiac magnetic
resonance
DCM = dilated cardiomyopathy
ECG = electrocardiogram
EF = ejection fraction
EP = electrophysiological
HCM = hypertrophic
cardiomyopathy
ICD = implantable
cardioverter-deﬁbrillator
LV = left ventricle
LVH = left ventricular
hypertrophy
LQTS = long QT syndrome
RV = right ventricular
SCD = sudden cardiac death
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829QTc duration. In particular, QTc duration (>500 ms) is
an independent predictor of cardiac events in patients
with LQTS1 and LQTS2 but not in those with LQTS3 (3).
The aforementioned electrical abnormalities result in
prolongation of contraction duration that may be
detected by usingmyocardial imaging (Figure 1). A study
in 101 genotyped subjects with LQTS revealed several
abnormalities when patients andmutation carriers were
compared with control subjects. Not only was the dura-
tion of contraction prolonged (determined by the time
interval from QRS complex to peak strain), but contrac-
tion was prolonged by variable durations in the exam-
ined left ventricular (LV) segments (4). Furthermore,
transmural differences were observed such that
contraction prolongation was more pronounced in the
subendocardial layer than in the mid-myocardial layer,
as reﬂected in longitudinal and circumferential strains,
respectively. There were interesting genotype–pheno-
type correlations seen in this investigation. The trans-
mural differences were most noticeable in patients with
double mutations (Jervell and Lange-Nielsen), followed
by those having LQTS2 and the least in patients with
LQTS1 (4). In a retrospective analysis, the mechanical
dispersion seen in longitudinal strain was a better pre-
dictorof events (arrhythmia, syncope, andcardiac arrest)
than QTc duration (4).
Thus, in the case of LQTS, myocardial imaging
seems to add to the genotype information, not only to
achieve better understanding of the extent of disease
but also in risk stratiﬁcation. Its role needs further
evaluation in prospective studies.
HYPERTROPHIC CARDIOMYOPATHY
Hypertrophic cardiomyopathy (HCM) affects w0.2%
of the population and is an important, potentially
preventable cause of SCD in young athletes, if diag-
nosed early and appropriate restrictions are applied
(5). Several mutations reportedly cause the disease
(Table 1). The likelihood of ﬁnding 1 of the causative
mutations is lower in sporadic cases versus familial
cases (30% to 40% vs. 60% to 70%). Previous publi-
cations emphasized the presence of malignant mu-
tations (more frequently in MYH7 and TNNT2), which
are characterized by younger age at presentation,
more severe LVH (but not for TNNT2 mutations), and
higher incidence of SCD. Recent reports noted an
overall lower incidence of such mutations in nonfa-
milial cases and inconsistency in their association
with a given phenotype and clinical outcome (6,7).
Furthermore, there is substantial heterogeneity in
phenotypic presentation even among patients with
the same mutation. Although HCM is an example of a
monogenic disorder, it is increasingly recognized thatgene–gene interactions, as well as gene–
environment interactions, determine a given
subject’s phenotype, withmore severe disease
in patients with multiple mutations (even if
they are apparently benign mutations) (8).
Presently, there is a limited role for genetic
testing in a given subject with known disease
to guide treatment decisions, although the
mere presence of a known mutation is associ-
ated with worse overall outcome irrespective
of the mutation type (9).
PATHOGENESIS OF IMAGING ABNORMALITIES
AND PRECLINICAL FINDINGS. Animal models
have been used to examine the development
of the classic phenotypic ﬁndings of LVH,
myocyte disarray and interstitial ﬁbrosis. In a
transgenic rabbit model of HCM (b-MyHC-
Q403), myocyte disarray occurred before
cellular hypertrophy and ﬁbrosis (10). The
transgenic rabbit model is interesting because
beta-myosin heavy chain is the predominant
protein, as in humans; this is unlike in mice, in which
alpha-myosin heavy chain is the predominant protein.
With respect to imaging ﬁndings, a reduction in septal
and lateral systolic and diastolic mitral annulus ve-
locities was the earliest observation when transgenic
mutant animals were compared with nontransgenic or
wild-type animals (11). Interestingly, myocardial ve-
locities were not related to disarray, hypertrophy, or
collagen volume fraction. Conversely, reduced cal-
cium sensitivity of myoﬁbrillar ATPase activity was
detected in these animals at the same time abnormal
myocardial function was observed by imaging. With
disease progression, stress-related signaling kinases
are activated and associated with the development of
LVH, a progressive increase inmyocyte cross-sectional
area and interstitial ﬁbrosis, and with further deterio-
ration of LV systolic and diastolic function. The ﬁnd-
ings in this animal model implicate defects in
myocardial bioenergetics as the primary abnormality
in the disease leading to myocardial dysfunction
before classic pathologic changes occur.
Models in transgenic mice (a-MyHC403/þ) found
other early abnormalities, including increased gene
transcription of molecules implicated in ﬁbrosis
(transforming growth factor-b and periostin) but
reduced transcripts of SERCA2a before the develop-
ment of LVH (12). These 2 ﬁndings may also help
explain the myocardial abnormalities detected by
imaging in early disease stages.
Similar to animal studies, there are several observa-
tions in humans (although not universally observed in
all studies) showing abnormal LV systolic and diastolic
function as detected by echocardiography (Figure 2)
FIGURE 1 Mechanical Dispersion in Long QT Syndrome
Left panel shows myocardial longitudinal strain signals from a normal subject; the right panel was obtained from a patient with prolonged QT syndrome. Notice the
homogeneous duration of contraction in the normal subject versus mechanical dispersion in the patient with prolonged QT interval. Reproduced with permission from
Oxford University Press, Haugaa KH, Edvardsen T, Leren TP, Gran JM, Smiseth OA, Amlie JP. Left ventricular mechanical dispersion by tissue Doppler imaging: a novel
approach for identifying high-risk individuals with long QT syndrome. Eur Heart J 2009;30:330–7.
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830and cardiac magnetic resonance (CMR) (13–16,17),
impaired energy metabolism (18), and increased serum
levels of C-terminal propeptide of procollagen type I
(19) in subjects with positive mutations but without
LVH.Otherﬁndings noted in preclinical disease include
mitral valve elongation, apical trabecular complexity,
and the presence of myocardial crypts (20–22). These
structural and functional abnormalities were not
related to any particular genotype and were limited to
relatively few patients. Interestingly, the results from a
recent study based on analysis of myocardial samples
(mostly from myectomy patients with missense muta-
tions) lend credence to the hypothesis recognizing
abnormal function as an important fundamental defect
that triggers secondary changes of LVH (23).
With respect to implications for management, the
consensus at the present time is that the generalguidelines for HCM patients with LVH should not be
applied to patients who carry known mutations but
lack hypertrophy. Recommendations with respect to
exercise activity and potential treatment to prevent
development of LVH and SCD await further observa-
tional and randomized clinical studies.
MOLECULAR , CELLULAR , AND FUNCT IONAL
HETEROGENEITY IN HCM . Heterogeneity in seg-
mental function is a hallmark of HCM that occurs
even in preclinical disease (13–16). Only a few studies
have attempted to explain these observations as they
relate to molecular and cellular heterogeneity. One
report assessed cardiac tissue from an HCM patient
with advanced heart failure but with preserved ejec-
tion fraction (EF) who underwent cardiac imaging
just before heart transplantation. Wide segmental
variation in the molecular expression of several
TABLE 1 Common Gene Mutations Reported With HCM
Locus Mutation
Myosin-binding protein C (MYBPC3); 15%–25% 11p11.2 Glu258Lys, Glu451Gln, Arg495Gln, Arg502Gln
Beta-myosin heavy chain 7 (MHC7); 15%–25% 14q11.2 Arg403Gln, Arg453Cys, Gly716Arg, Arg719Trp
Alpha-myosin heavy chain 6 (MHC6); <1% 14q11.2–q12 Gln1065His
Cardiac troponin T (TNNT2); <5% 1q32 Phe70Leu, Arg102Leu, Pro120Val, Arg286Cys
Cardiac troponin I (TNNI3); <5% 19p13.4 Arg141Gln, Ala157Val, Arg162Po, Arg186Gln
Cardiac troponin C (TNNC1); <1% 3p21.1 Leu29Gln, Ala8Val, Cys84Tyr, Cys35Ser
Alpha-tropomyosin (TPM1); <5% 15q22.2 Asp175Asn; Glu180Gly
Alpha-actin (ACTC1); <1% 15q14 Ala295Ser
Alpha-actinin 2 (ACTN2); <1% 1q43 Ala119Thr, Thr495Met, Glu583Ala, and Glu628Gly
Myosin regulatory light chain 2 (MYL2); <2% 12q24.11 Phe18Leu, Arg58Gln
Essential myosin light chain 3 (MYL3); <1% 3p21.31 E56G
Myozenin 2 (MYOZ2); <1% 4q26 Ser48Pro, Ile246Met
Telethonin (TCAP); <1% 17q12 Thr137Ile, Arg153His
Phospholamban (PLN); <1% 6q22.31 77A-G, 42C-G (both in gene promoter region)
Junctophilin 2 (JPH2); <1% 20q12 Ser101Arg, Tyr141His, Ser165Phe
Muscle LIM protein (CSRP3); <1% 11p15.1 Leu44Pro, Ser54Arg/Glu55Gly, Cys58Gly
Titin (TTN); <1% 2q24.3 Arg740Leu, Ser3799Tyr
In part from Bos et al. (6) and the Online Mendelian Inheritance in Man database. The table presents examples and does not include all mutations.
HCM ¼ hypertrophic cardiomyopathy.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 7 , 2 0 1 5 Nagueh and Zoghbi
J U L Y 2 0 1 5 : 8 2 8 – 4 5 Role of Imaging in SCD
831genes/proteins was present, including myosin, titin,
B-type natriuretic peptide, and collagen I and III, as
well as mitochondrial DNA content and 4 key en-
zymes of the electron transport chain. The more
compromised performance of the septum compared
with the lateral wall was associated with increased
cellular hypertrophy, myocyte disarray, interstitial
ﬁbrosis, and a lower mitochondrial respiratory con-
trol ratio for all substrates (24). The effects of local
loading conditions on gene and protein expression
were not examined but could be important contrib-
uting factors to the segmental variation seen in
myocardial function.
RECOMMENDATIONS FOR RISK STRATIFICATION OF
SCD. Genotyping does not have a practical role in risk
stratiﬁcation for SCD given the inconsistent relations
noted with SCD (as discussed earlier). Conversely,
clinical and imaging data are useful, including family
history of SCD, unexplained syncope, nonsustained
ventricular tachycardia, LV maximum wall thick-
ness $3 cm, and abnormal blood pressure response to
exercise (5). Both echocardiography and CMR
(Figures 3 and 4) can be used to assess the extent of
LVH (25), with echocardiography providing additional
data on LV ﬁlling pressures, which can predict higher
risk of SCD in HCM (26,27). CMR can be used to detect
the presence and extent of regions with replacement
ﬁbrosis (28,29) and increased extracellular volume
using late gadolinium enhancement (30,31). Although
delayed enhancement is a predictor of adverse events
in general (28,29,32–33), its role as an independent
marker of SCD remains to be established. The mostrecent guidelines advocate its utility in borderline
cases (5). Intuitively, a larger defect (>5%) portends a
higher risk, but this claim awaits ongoing multina-
tional registry results. HCM patients with LV systolic
dysfunction and depressed LV EF are also at
increased risk for SCD, and they warrant treatment
similar to patients in heart failure with reduced EF.
RECOMMENDATIONS FOR GENETIC SCREENING
AND ROLE OF IMAGING. After the diagnosis of HCM is
established, genetic testing is offered to the patient. In
the presence of an identiﬁable mutation, genetic
testing can be extended to ﬁrst-degree relatives. When
a causative mutation is identiﬁed, relatives should
undergo clinical evaluation, in addition to electrocar-
diogram (ECG) and echocardiography and/or CMR in
situations with suboptimal images on echocardiogra-
phy. In the absence of LVH, regular follow-up should
take place at yearly intervals during the adolescent
years and every 5 years in relatives past this age. The
algorithm with respect to genetic testing (Figure 5)
cannot be applied if the patient does not have a known
mutation. In the latter situation, regular clinical eval-
uation and imaging should still be offered with an age-
dependent frequency as indicated earlier (5).
MONOGENIC METABOLIC DEFECTS
ASSOCIATED WITH SCD
Some lysosomal enzyme defects and glycogen storage
diseases (34) are associated with LVH and arrhyth-
mias. These include Fabry disease (Figure 6), Danon
disease, and PRKAG2 deﬁciency (disease causing
FIGURE 2 Development of LVH in an HCM Patient With Age-Reduced TD Mitral Annulus Velocities
(A) Parasternal long- and short-axis views and tissue Doppler (TD) velocities at the lateral and septal side of the mitral annulus from a 20-year-old subject carrying
a known mutation for hypertrophic cardiomyopathy (HCM). Left ventricular hypertrophy is absent, but systolic (Sa) and early diastolic (Ea) velocities are reduced for age.
(B) After 2 years, asymmetric septal hypertrophy developed, and TD annular velocities remain reduced. AO ¼ aorta; Aa ¼ late diastolic velocity; LA ¼ left atrium;
LV ¼ left ventricle; RV ¼ right ventricle. Reproduced with permission from Nagueh SF and Mahmarian JJ. Noninvasive cardiac imaging in patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol 2006;48:2410–22.
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832mutations in the gene for the gamma 2 regulatory
subunit of adenosine monophosphate–activated pro-
tein kinase). Of the 3 diseases, Danon disease has a
malignant course whereby it leads to heart failure and
SCD at a young age. For patients with Fabry disease,
SCD per se is rare in the absence of LV systolic
dysfunction. In patients with PRKAG2 deﬁciency,
arrhythmias due to accessory pathways may occur, as
well as high-grade atrioventricular block, but SCD is
not common.
With respect to the diagnosis of Danon disease, the
presence of massive LVH, Wolff-Parkinson-White
syndrome ﬁndings on ECG, mental changes, and
skeletal myopathy should raise suspicion, which can
be conﬁrmed by analysis of the lysosome-associated
membrane protein 2 gene. Cardiac disease can be
manifested by HCM or dilated cardiomyopathy
(DCM), and it affects both male and female subjects.DILATED CARDIOMYOPATHY
Idiopathic DCM includes diseases caused by genetic
defects and is an important cause of heart failure and
SCD. The disease had a prevalence of 1:2,500 in
1 study (35). There is an asymptomatic stage of LV
systolic dysfunction characterized by LV remodeling
and depressed EF, which is usually followed by a
symptomatic stage. DCM has a number of environ-
mental factors that lead to its development, as do
toxins, drugs (chemotherapeutic drugs), and endo-
crine and infectious diseases. In addition, these fac-
tors can modulate disease presentation in patients
with genetic predisposition.
DCM occurs in sporadic or familial cases. Patterns
of inheritance include autosomal dominant, auto-
somal recessive, and X-linked. Familial disease is
present when at least 2 family members meet the
FIGURE 4 CMR and Diastolic Doppler Signals From HCM Patient With Asymmetric LVH
An example of cardiac magnetic resonance (CMR) and Doppler velocities from a patient with HCM and asymmetric LV hypertrophy. In the upper panels, the arrows show
areas of delayed gadolinium hyperenhancement in the short-axis and 4-chamber views. The bottom panels show mitral inﬂow and tissue Doppler velocities at the septal
and lateral sides of the mitral annulus. Both early diastolic (e’) and late diastolic (a’) velocities are reduced and the ratio of mitral inﬂow early diastolic velocity (E) to e’
velocity is increased to >20 at the septal and lateral sites consistent with elevated LV ﬁlling pressures. Abbreviations as in Figures 2 and 3.
FIGURE 3 Apical LV Aneurysm in Patient With Apical HCM
Two-dimensional echocardiographic imaging with contrast from a patient with apical HCM and an apical aneurysm, a ﬁnding that represents a
higher risk for sudden cardiac death (SCD). Left panel displays left ventricular (LV) volume at end diastole, and the right panel shows LV
volume at end systole. Notice the presence of mid-cavity obliteration with apical ballooning at end systole. Abbreviation as in Figure 2.
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FIGURE 5 Algorithm for Screening Relatives of Patients With HCM
Algorithm showing the role of genetic testing and imaging in familial screening for HCM. ECG ¼ electrocardiogram; other abbreviations as in
Figures 2 and 4.
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834diagnostic criteria after excluding other causes of
DCM. Imaging plays an important role in establishing
the diagnosis and assessing response to treatment, as
well as predicting outcome and screening of ﬁrst-
degree relatives. Echocardiography is often the ﬁrst
modality used for clinical evaluation, and it provides
data on LV volumes, mass, and EF, as well as left
atrial volumes and function, LV diastolic function,
pulmonary artery pressures, and right ventricular
(RV) function (Figure 7). CMR can be valuable in
patients with suboptimal echocardiographic images
and can direct attention to the presence of coronary
artery disease with subendocardial scarring, abnor-
mally short T2 relaxation times in hemochromatosis,
or increased T2 heterogeneity in Duchenne muscular
dystrophy (36). Delayed enhancement has been
observed with variable frequency and seems depen-
dent on the stage of the disease. The usual pattern is
mid-wall ﬁbrosis (37).
DCM can be an isolated ﬁnding or part of a
clinical syndrome in which other organs are affected.
These syndromes include Emery-Dreifuss musculardystrophy, limb-girdle muscle dystrophy, Duchenne
and Becker muscular dystrophies, and Kearns-Sayre
syndrome. In addition to cardiac involvement, pa-
tients with these syndromes present with muscle
weakness of special muscle groups and elevated
creatine kinase levels. Table 2 displays a list of DCM-
causing mutations (38,39). A recent study noted that
mutations in the A-band region of TTN are frequent
causes of the disease (they were detected in 27% of
patients with DCM) (40). As shown in Tables 1 and 2,
different mutations in the same gene (MHC7, MHC6,
MYBPC3, TNNT2, TNNC1, TNNI3, TPM1, ACTC1,
ACTN2, PLN, and TTN) can cause DCM and HCM. In
addition, there are genetic mutations that are associ-
ated with both DCM and HCM (MYBPC3: Ala833Thr,
Gly490Arg;TNNT2: Ile79Asn; PLN: Leu39Ter). Of note,
SCN5A mutations can also present with LQTS3 and
ventricular arrhythmias. Although somemutations are
associated with a malignant phenotype as LMNA mu-
tations (high incidence of conduction system disease
and SCD), it is not possible to predict the actual geno-
type in most patients based only on the phenotype.
FIGURE 6 Echocardiographic Findings From a Patient With Fabry Disease
Two-dimensional and Doppler echocardiographic imaging from a male patient with Fabry disease. The upper panels show the parasternal views demonstrating the
presence of LV hypertrophy in all myocardial segments, albeit more prominent in the anteroseptal and anterolateral segments. The lower left panel shows no signiﬁcant
LV outﬂow gradient with a Valsalva maneuver. Mitral inﬂow in the middle panel shows pseudonormal LV ﬁlling (grade II) diastolic dysfunction with reduced lateral e’
velocity (lower right panel). Abbreviations as in Figures 3 and 4.
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835MOLECULAR AND CELLULAR CORRELATES OF
CARDIAC FUNCTION IN PATIENTS WITH DCM. Sev-
eral abnormalities in the calcium cycling proteins
have been reported in DCM, including reduced
expression of SERCA2a, and in some patients, the
disease is due to PLN mutations (e.g., Arg9Cys,
Arg14Del, LeuStop), which can lead to loss of func-
tion. In addition, the extent of ﬁbrosis is often
considered an important determinant of cardiac
function in patients with DCM. However, recent
studies have challenged this association because
there was no signiﬁcant correlation between Doppler
parameters of LV diastolic function such as the E/e0
ratio, deceleration time, and the extent of delayed
enhancement by CMR (Figure 8) (41). Conversely,
signiﬁcant correlations were present between LV
EF, mitral annulus e0 velocity, pulmonary capillary
wedge pressure, LV end-diastolic volume/pulmonarycapillary wedge pressure ratio, global strain, seg-
mental and global diastolic strain rates, and mRNA
expression of TTN N2B, TTN N2BA, SERCA2a, and
PLN, and protein levels of SERCA2a and phosphory-
lated PLN (r range 0.53 to 0.95; all p < 0.05) in pa-
tients with end-stage DCM. However, weak to no
associations were present between strain and inter-
stitial ﬁbrosis and its molecular determinants (42).
Thus, myocardial dysfunction in DCM is not neces-
sarily irreversible, and it is possible to improve car-
diac function with treatment that can increase the
expression of SERCA 2a or alter the phosphorylation
status of TTN and PLN. Increased expression of
SERCA 2a is undergoing evaluation in a clinical
trial (43).
SCREENING: GENETIC TESTING/IMAGING AND PRE-
CLINICAL DIAGNOSIS. Clinical evaluation of ﬁrst-
degree family members can be complemented by
FIGURE 7 Echocardiographic Findings From a Patient With Advanced DCM
Two-dimensional echo and Doppler ﬁndings from a patient with muscular dystrophy and severe biventricular heart failure. The upper panels show end-diastolic and
end-systolic echocardiographic frames consistent with severely depressed LV systolic function. The lower left panel shows a right ventricular (RV) clot (arrow).
Both mitral inﬂow (middle panel) and hepatic venous ﬂow (right panel) are consistent with elevated LV and RV ﬁlling pressures, respectively. Mitral inﬂow shows
restrictive LV ﬁlling with an E/A ratio >2 (grade III diastolic dysfunction), whereas hepatic venous ﬂow shows only diastolic antegrade ﬂow with increased amplitude
and duration of atrial reversal velocity (Ar). Collectively, the ﬁndings predict a high mortality risk. DCM ¼ dilated cardiomyopathy; other abbreviation as in Figure 3.
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836genetic testing. In the presence of a known mutation
in a proband, molecular genetic analysis is feasible,
although there is variable penetrance. Clinical eval-
uation of DCM includes physical examination to
detect signs of cardiomegaly and heart failure; the
evaluation also includes ECG, echocardiography, and
CMR, as indicated. Few data are available on the
presence of abnormal systolic function detected by
myocardial velocities and strain before LV remodel-
ing and depressed EF (44). Additional longitudinal
studies are needed before the latter approach is rec-
ommended. However, genetic testing is not useful if
the patient does not have a known mutation.
RISK STRATIFICATION FOR SCD AND ROLE OF
IMAGING. A number of observational studies assessed
the predictors of SCD in patients with DCM. Para-
meters included family history, QRS duration,T-wave alternans, mechanical dyssynchrony, LV end-
diastolic dimension, LV EF, and the extent of delayed
enhancement by CMR, with a more deranged
LV function portending a worse outcome (45,46).
Overall, genetic analysis has a limited role for
risk stratiﬁcation except for patients with LMNA
mutations, which are associated with a high risk
of SCD.
LV NONCOMPACTION
LV noncompaction is rare in adults, with a prevalence
of 0.014% (47). The basic morphological ﬁnding in
noncompaction is the presence of a thicker endocar-
dial layer with spongy or noncompacted myocardium
and a thinner epicardial layer (ratio $2, according to
echocardiography). There are myocardial recesses
TABLE 2 Common Gene Mutations Reported With DCM
Locus Mutation
Titin (TTN); 18%–25% 2q31.2 Truncating mutations in A-band region; Trp930Arg; Ala743Val
Lamin-A/C (LMNA); 6% 1q22 Asn195Lys; Arg571Ser; Glu161Lys; Arg541Gly
Beta-myosin heavy chain 7 (MHC7); 4.2% 14q11.2 Ser532Pro; Phe764Leu; Ala223Thr; Ser642Leu
Alpha-myosin heavy chain 6 (MHC6); 3%–4% 14q11.2 Pro830Leu; Ala1004Ser; Glu1457Lys
Sodium channel protein type 5 subunit alpha (SCN5A); 2%–4% 3p22.2 Thr220Ile; Asp1595His; Arg222Gln; Ile1835Thr
Myosin binding Protein C (MYBPC3); 2%–4% 11p11.2 Asn948Thr; Cys1264Phe
Cardiac troponin T (TNNT2); 2.9% 1q32 Lys 210 Deletion; Arg141Trp; Arg205Leu; Asp270Asn
BAG family molecular chaperone regulator 3 (BAG3); 2.5% 10q26.11 Exon 4 Deletion; Arg71Trp; Leu462Pro; Arg218Trp
LIM domain binding protein 3 (LDB3); 1% 10q23.2 Ile352Met; Lys136Met
Cardiac troponin I (TNNI3); 1.3% 19q13.4 Lys36Gln; Asn185Lys
Cardiac troponin C (TNNC1); <1.0%–1.3% 3p21.1 Gly159Asp
Alpha-tropomyosin (TPM1); <1.0%–1.9% 15q22.2 Glu54Lys; Glu40Lys
Vinculin (VCL); 1% 10q22.2 3-BP Deletion (2862GTT) in exon 19 with leu954 deletion
Alpha-actin (ACTC1); <1% 15q14 Arg12His; Glu361Gly
Alpha-actinin 2 (ACTN2); <1% 1q43 Gln9Arg
Muscle LIM protein (CSRP3); <1% 11p15.1 Lys69Arg
Desmin (DES); <1% 2q35 Ile451Met
Delta-sarcoglycan (SGCD); <1% 5q33.2-q33.3 3-BP Deletion (710AGA/711GAA) in exon9p with lys238 deletion
Phospholamban (PLN) 6q22.31 Arg9Cys; 3-BP Del. (39AGA) with Arg14 del.; 36A-C transversion
Dystrophin (DMD) Xp21.2-p21.1 Exon 1 deletion; IVS1, G-T, þ1; Thr279Ala; ALU INS
From Ray E. Hershberger and Ana Morales: Dilated Cardiomyopathy in GeneReviews and the Online Mendelian Inheritance in Man database. The table presents examples and
does not include all mutations.
DCM ¼ dilated cardiomyopathy.
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837that communicate with the LV cavity. Numerous
diagnostic criteria have been published by several
investigators who compared the ﬁndings in this group
of patients versus those without the disease and used
that approach to support their criteria (48). Most
frequently, the pathological ﬁndings are noted in the
LV apex and mid-segments of the inferior and lateral
walls (47). However, there are important differences
between the criteria, including the time of measure-
ment of wall thickness ratio (end diastole versus end
systole), presence of apical location of >3 trabecula-
tions, and presence or absence of congenital heart
defects. Irrespective of the criteria used, prominent
trabeculations that can be observed in subjects
without cardiac disease should be distinguished from
noncompaction.
In general, there are 2 schools of thought: 1 that
considers the disease as a unique cardiomyopathy
and another with the view that it could be the mani-
festation of several unrelated disorders. In support of
the latter point of view, LV noncompaction has been
noted in patients with HCM, restrictive cardiomyop-
athy, and arrhythmogenic right ventricular cardio-
myopathy (ARVC) (47).
Table 3 displays some of the reported mutations
associated with the noncompaction phenotype
(49–52). Although it is generally believed that the
normal process of development is interfered withand leads to the abnormal morphology, the disease
can be acquired (i.e., abnormal ﬁndings have been
detected later in life in patients who had had prior
normal examinations). These ﬁndings reinforce the
notion that the cardiac phenotype per se of a given
subject may not allow the identiﬁcation of the un-
derlying mutation. Nevertheless, recent reports of
HCN4 mutations suggest that noncompaction, when
associated with mitral valve prolapse and brady-
cardia, should raise suspicion of mutations in the
latter gene (51,52).
ABNORMAL LV STRUCTURE AND FUNCTION
IDENTIFIED BY IMAGING. Both transthoracic echo-
cardiography, including the use of intravenous
contrast agents, and CMR can be used to evaluate
patients who have noncompaction. LV EF varies
from normal to depressed (Figures 9 and 10, Online
Video 1). CMR can further measure the mass of
noncompacted myocardium (53), and this ﬁnding
has been used to establish the diagnosis by some
investigators (noncompacted mass >20% of total LV
mass). For accurate measurements of LV wall
thickness by echocardiography, short-axis views
that are dependent on axial resolution should be
used, with care taken to avoid off-axis planes. LV
pathology includes features of DCM and HCM as
well as RV involvement. Myocardial function is
abnormal and can be detected by impaired strain,
FIGURE 8 CMR and Doppler Signals From 2 Patients With DCM
CMR and TD recordings from 2 patients with DCM. The top panels display 3 CMR short-axis slices followed by 3 long-axis slices. To the left, there is patchy scar
distribution in LV base and the mid- and apical regions (red arrows). To the right, there are no areas with delayed hyperenhancement. Both patients have similarly
reduced annular early diastolic velocity (e’) at septal and lateral sides of the mitral annulus (a’ [late diastolic mitral annular velocity]) with and without delayed
hyperenhancement with gadolinium. Reproduced with permission from Malaty et al. (41). Abbreviations as in Figures 2, 3, 4, and 7.
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838abnormal torsion patterns (the LV base and apex
rotate in the same direction as opposed to opposite
directions in subjects without noncompaction), and
LV diastolic dysfunction with segmental and globalTABLE 3 Common Gene Mutations Reported With LV Noncompaction
Loc
Tafazzin (TAZ)* Xq2
Lamin-A/C (LMNA) 1q22
Beta-myosin heavy chain 7 (MHC 7) 14q1
Alpha-dystrobrevin (DTNA) 18q1
Hyperpolarization-activated cyclic nucleotide channel 4 (HCN4) 15q2
Myosin binding protein C (MYBPC3) 11p1
Cardiac troponin T (TNNT2) 1q32
LIM domain binding protein 3 (LDB3) 10q2
Mindbomb homolog 1 (MIB1) 18q1
Ryanodine receptor 2 (RYR2 ) 1q43
Alpha-tropomyosin (TPM1) 15q2
Alpha-actin (ACTC1) 15q1
From the Online Mendelian Inheritance in Man database. *The mutations identiﬁed in
neutropenia, and skeletal myopathy with increased urinary levels of 3-methylglutaconic
LV ¼ left ventricular.LV function abnormalities (54,55). Similar to other
cardiomyopathic disorders, the disease can be
diagnosed for the ﬁrst time in children or adults. It
is important to use imaging resources successfullyus Mutation
8 Gly197Arg, Cys118Arg 1-BP INS (exon 7), IVS2, G-A, -1
Arg110Ser, Lys117Arg
1.2 Leu1793Pro, Arg243His, Ala1766Thr, Tyr283Asp, Asn1918Lys
2.1 Pro121Leu
4.1 Gly482Arg
1.2 Gly490Arg, Pro873Leu, 2-BP DEL, 2919CT
Arg131Trp
3.2 Ser196Leu, Thr213Ile, Asp117Asn, Asp626Asn
1.2 Val943Phe
Exon 3 deletion
2.2 Lys248Glu, Glu192Lys
4 Glu101Lys
this gene are associated with Barth syndrome (characterized by cardiomyopathy,
acid).
FIGURE 9 Echocardiographic Findings From a Patient With LV Noncompaction
The ﬁgure shows the ﬁndings on 2-dimensional echocardiographic imaging of an LV apical long-axis view from a patient with LV
noncompaction. Multiple trabeculations and recesses in the inferolateral wall at (left) end diastole and (right) end systole are displayed.
Abbreviation as in Figure 3.
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839to identify mural thrombi because their presence
has direct implications for management and the
administration of anticoagulants.
Clinically, presentation varies, from asymptomatic
family members with the classic morphology to pa-
tients with heart failure, embolic events, and SCD. In
addition, LV noncompaction can be present as 1 of the
manifestations of clinical syndromes in which skel-
etal myopathy occurs (e.g., Barth syndrome) (Table 3).
Implantable cardioverter-deﬁbrillator (ICD) implan-
tation is guided by the presence or absence of sus-
tained ventricular tachycardia, LV remodeling, extent
of noncompaction, and LV EF, among other parame-
ters of myocardial function; few data exist overall,
however.FIGURE 10 CMR Findings From a Patient With LV Noncompaction
The ﬁgure displays the ﬁndings by CMR from another patient with LV non
themiddle panel is the LV short-axis view at end systole; and the right p
trabeculations and recesses. See Online Video 1. Abbreviations as in FigSCREENING OF FAMILY MEMBERS. For patients with
LV noncompaction, identiﬁcation of a known muta-
tion can help inform the recommendation to offer
genetic testing to relatives. In the absence of a known
mutation, ﬁrst-degree family members should be
screened by using clinical evaluation, ECGs, and
echocardiography at 3-year intervals. When the rela-
tive is known to carry the mutation, screening in
childhood should be considered at yearly intervals
and for adults at 1- to 3-year intervals (47).
ARRHYTHMOGENIC RV CARDIOMYOPATHY
ARVC is an important cause of SCD in younger sub-
jects and athletes and usually has an autosomalcompaction. Left panel shows the LV short-axis view at end diastole;
anel presents the LV 4-chamber view. Notice the presence of multiple
ures 3 and 4.
FIGURE 11 Cartoon of Cellular Location of Proteins Implicated in Pathogenesis of ARVC
The ﬁgure illustrates the location of several intercalated disc proteins associated with arrhythmogenic right ventricular cardiomyopathy (ARVC).
Each grey line is a cell membrane, and the area in-between is the cell-to-cell contact area. APC ¼ adenomatous polyposis coli (a tumor
suppressor gene that provides a platform for the beta-catenin destruction complex [BDC]); Axin ¼ also part of the BDC that regulates stability
of the b-cat in Wnt-signaling pathway; b-cat ¼ beta-catenin; CDH ¼ cadherin; CK1 ¼ casein kinase 1 that targets b-cat for phosphorylation;
DSC ¼ desmocollin; DSG ¼ desmoglein; DSP ¼ desmoplakin; Dvl ¼ disheveled [a cytoplasmic protein involved in canonical and noncanonical
Wnt-signaling pathways]; GSK3b ¼ glycogen synthase kinase 3 beta and known to phosphorylate b-cat; JUP ¼ junction plakoglobin; LRP5/6 ¼
low-density lipoprotein receptor–related proteins 5 and 6 (transmembrane receptors involved with receptor-mediated endocytosis and
transduction of canonical Wnt signals); NF2 ¼ neuroﬁbromin 2 (an upstream molecule of Hippo signaling pathway also known as Merlin
[acronym for Moesin-Ezrin-Radixin-like protein], which is a tumor suppressor); PKP-2 ¼ plakophilin-2; PKCa ¼ protein kinase C alpha;
Wnt ¼ after Drosophila melanogaster wingless gene.
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840dominant pattern of inheritance, with a prevalence of
w1:1,000 with variable penetrance. Pathologically,
RV myocardium is replaced with ﬁbrous tissue and
fatty inﬁltration and is an important cause of SCD in
athletes.
GENETIC MUTATIONS. Mutations were identiﬁed
in several genes that code for desmosomal and
nondesmosomal proteins (Figure 11). For desmo-
somal proteins, these include desmoplakin (DSP),
plakophilin-2 (PKP2), plakoglobin (JUP), desmo-
collin-2 (DSC-2), and desmoglein-2 (DSG-2). ForTABLE 4 Common Gene Mutations Reported With ARVC
Locus
Plakophilin-2 (PKP2) 12p11.21
Desmoglein-2 (DSG2) 18q12.1
Desmocollin-2 (DSC2) 18q12.1
Desmoplakin (DSP) 6p24.3
Junction plakoglobin (JUP) 17q21.2
Ryanodine receptor 2 (RYR2) 1q43
Transmembrane protein 43 (TMEM43) 3p25.1
Transforming growth factor beta-3 (TGFB3) 14q24.3
From the Online Mendelian Inheritance in Man database. The table presents examples a
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy.nondesmosomal proteins, they include transforming
growth factor-b3 (TGFB3), ryanodine receptor 2
(RYR2), and transmembrane protein 43 (TMEM43)
(Table 4). In addition, some patients harbor multiple
mutations (56), both compound (both alleles of the
same gene) and digenic (mutations in 2 different
genes). Clinically, RV dysfunction can be an isolated
ﬁnding or a component of a clinical syndrome.
These include Naxos disease, which is char-
acterized by palmoplantar keratoderma and woolly
hair with autosomal recessive inheritance (57), andMutation
Lys654Gln, Phe424Ser, Ser140Phe, V837fsX930
Arg45Gln, Arg48His, Trp305X, Cys506Tyr, Gly811Cys
1-BP DEL (exon 12), 1841G
Ser299Arg
Ser39_Lys40insSer
Asn2386Ile, Leu433Pro,
Ser358Leu, Ala57Thr
1723C >T in 30 untranslated region
nd does not include all mutations.
TABLE 5 Diagnostic Criteria for ARVC
Major Minor
Family history Diagnosis conﬁrmed in ﬁrst-degree relative by imaging,
ECG, or pathology criteria
Pathogenic mutation on genetic testing
History of disease or SCD in ﬁrst-degree relative but
diagnosis not conﬁrmed
Conﬁrmed diagnosis in second-degree relative
ECG and arrhythmias Inverted T in V1–V3 (all 3 leads) without RBBB
(>14 years)
Epsilon waves in V1–V3
NSVT or sustained VT with LBBB and LAD or
indeterminate axis
Inverted T in V and V2 or V4–V6 (without RBBB)
Inverted T in V1–V4 with RBBB
Late potential by signal-averaged ECG
Terminal QRS duration $38 ms
Filtered QRS duration $114 ms
Terminal QRS activation duration >55 ms
Root mean square voltage of terminal 40 ms #20 Uv
NSVT or sustained VT with RVOT or LBBB and RAD
or unknown axis
PVC frequency >500/day
Pathology Fibrous tissue in RV free wall with or without fatty
tissue and <60% residual myocytes in $1 sample
Fibrous tissue in RV free wall with or without fatty tissue
and 60%–75% residual myocytes in $1 sample
Echocardiography RV regional dysfunction
þ
RVOT $32 mm (PLAX)
Or
RVOT $36 mm (PSAX)
Or
FAC #33%
RV regional dysfunction
þ
RVOT $29 to <32 mm (PLAX)
Or
RVOT $32 to <36 mm (PSAX)
Or
FAC >33% to #40%
CMR RV regional dysfunction
þ
RV EDV index $110 ml/m2 in male subjects
and $100 ml/m2 in female subjects
Or
RVEF #40%
RV regional dysfunction
þ
RV EDV index $100 ml/m2 (male subjects)
to <110 ml/m2 ($90 to <100 in female subjects )
Or
RVEF >40% to #45%
Adapted from Marcus et al. (59).
CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; EDV ¼ end-diastolic volume; FAC ¼ fractional area change; LAD ¼ left anterior descending artery; LBBB ¼ left
bundle branch block; NSVT ¼ nonsustained ventricular tachycardia; PLAX ¼ parasternal long-axis view; PSAX ¼ parasternal short-axis view; PVC ¼ premature ventricular
complexes; RBBB ¼ right bundle branch block; RV ¼ right ventricular; RVEF ¼ right ventricular ejection fraction; RVOT ¼ right ventricular outﬂow tract; SCD ¼ sudden cardiac
death; VT ¼ ventricular arrhythmia; other abbreviation as in Table 4.
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841Carvajal syndrome (autosomal recessive inheri-
tance), which has similar ﬁndings to Naxos disease
in addition to prominent LV involvement with
DCM (58).FIGURE 12 CMR Findings From a Patient With ARVC
Long-axis, 4-chamber view with CMR showing delayed hyper-
enhancement (red arrows) in the RV free wall from a patient with
ARVC. See Online Video 2. Abbreviations as in Figures 4, 7, and 11.Molecular genetic analysis is available with the use
of multigene panels and can be applied to relatives of
patients with clinical ﬁndings of the disease who have
a known mutation. This approach is particularly
useful because patients may carry double mutations.
Of note, some of the asymptomatic relatives with
positive mutations have abnormal RV function
detected by imaging. In general, the phenotype ge-
notype relation is weak, and marked phenotypic
variation has been observed for the same mutation.
Notwithstanding, there are distinct phenotypes that
can predict the genetic mutation in some patients, as
speciﬁc DSP mutations are associated with Carvajal
syndrome and JUP mutations with Naxos disease.
DIAGNOSTIC CRITERIA AND THE ROLE OF IMAGING.
Major and minor criteria have been proposed to
establish a diagnosis of ARVC. A deﬁnite diagnosis is
established in the presence of 2 major, 1 major and
2 minor, or 4 minor criteria from different categories
(59). These criteria can be ascertained by echocardi-
ography and/or CMR (Online Video 2). Major criteria by
either modality include regional RV dysfunction, RV
enlargement (based on RV dimensions by echocardi-
ography or end-diastolic volume index by CMR), or
more compromised RV global systolic dysfunction
TABLE 6 Role of Imaging in Monogenic Disorders Associated With Increased Risk of SCD
Role of Imaging
Primary EP diseases Unveils the relation between electrical and functional abnormalities
Potential role for mechanical dispersion in identifying patients at higher risk for SCD
HCM Establishes diagnosis in the presence of unexplained LV hypertrophy
Identiﬁes patients at high risk for SCD: maximum wall thickness $3 cm, EF <50%, DE by CMR?
Familial screening in conjunction with genetic testing
Help target treatment and assess response to therapy in obstructive HCM
Metabolic defects Identiﬁes the presence of cardiac pathology in patients with systemic forms of the disease and in those with cardiac variant of Fabry disease
Can help target treatment based on functional abnormalities (e.g., patients with heart failure and depressed EF, heart failure with
normal EF, rare cases of Fabry disease with dynamic LVOT obstruction)
DCM Establishes diagnosis in presence of unexplained LV dilation with systolic dysfunction
Identifying higher risk for SCD (LV size, systolic and diastolic dysfunction, dyssynchrony, potential role for delayed hyperenhancement by CMR)
Assess response to therapy (reverse LV remodeling and improvement in LV ﬁlling pattern)
Familial screening in conjunction with genetic testing
LV noncompaction Establishes diagnosis: endocardial layer with noncompacted myocardium
Familial screening in conjunction with genetic testing
ARVC Establishes diagnosis in the presence of RV enlargement/dysfunction
Potential role for identifying patients at high risk for SCD based on LV dysfunction and RV pathology
Familial screening, in conjunction with genetic testing
EF ¼ ejection fraction; EP ¼ electrophysiological; other abbreviations as in Tables 1 to 5.
TABLE 7 Multimoda
Echocardiography M
P
R
G
CMR M
P
R
(
Cardiac CT M
C
G
SPECT/PET L
C
R
The use of ? denotes that
CAD ¼ coronary artery d
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842(fractional area change by echocardiogram or RV EF
by CMR). Pathological ﬁndings according to biopsy
results, family history, ECG abnormalities, and ar-
rhythmias can also be used to establish the diagnosis
(Table 5). Of note, both 3-dimensional echocardiogra-
phy and speckle tracking echocardiography can
provide a more accurate assessment of regional RV
function than standard 2-dimensional imaging, in-
cluding in asymptomatic gene carriers (60,61). Impor-
tantly, CMR (and computed tomography) can identify
the presence of ﬁbrofatty replacement of RV myocar-
dium and replacement ﬁbrosis by using delayed
hyperenhancement (Figure 12, Online Video 2).
IMAGING AND RISK STRATIFICATION OF SCD. SCD
can occur in asymptomatic subjects as well in those
with overt disease. Few data are available on thelity Imaging in Monogenic Cardiac Disorders Associated With Increased R
HCM DCM
orphology and function
reclinical diagnosis and screening
isk stratiﬁcation for SCD
uiding septal reduction therapy
Morphology and function
Screening
Risk stratiﬁcation for SCD
orphology and function
reclinical diagnosis and screening
isk stratiﬁcation for SCD
including potentially delayed
hyperenhancement)
Morphology and function
Screening
Risk stratiﬁcation for SCD
(including delayed
hyperenhancement)
orphology and systolic function
AD diagnosis
uiding alcohol septal ablation
Morphology and systolic function
Evaluate for possible CAD
V volumes and EF
AD diagnosis
isk stratiﬁcation for SCD (potential)
LV volumes and EF
Evaluate for possible CAD
it is not deﬁnitive though there are data that suggest this potential role could be of value
isease; CT ¼ computed tomography; PET ¼ positron emission tomography; SPECT ¼ single-prognostic role of imaging in ARVC, although ﬁndings
from a CMR study suggest that the presence of mul-
tiple RV abnormalities portends a worse outcome
(62). At the present time, ICD therapy is guided by
clinical and EP ﬁndings, including family history of
SCD, presence of ventricular arrhythmias, syncope,
positive EP study results, and LV dysfunction (63,64).
CONSIDERATIONS FOR GENETIC TESTING AND
ROLE OF IMAGING. As detailed in Table 5, imaging
plays an important role in establishing a diagnosis.
Once the diagnosis is established, genetic testing can
be offered to identify ﬁrst-degree relatives with pos-
itive mutations (overall yield of genetic testing is
w50%). This strategy is contingent on identifying a
known mutation in the proband. Genetic testing is
usually not needed to conﬁrm the clinical diagnosis.isk of SCD
LV Noncompaction ARVC
Morphology and function
Screening
Risk stratiﬁcation for SCD (?)
Morphology and function
Screening
Risk stratiﬁcation for SCD (?)
Morphology and function
Screening
Risk stratiﬁcation for SCD (?)
Morphology and function
Screening
Risk stratiﬁcation for SCD (?)
Morphology and systolic function
Evaluate for possible CAD
Morphology and systolic function
Evaluate for possible CAD
LV volumes and EF
Evaluate for possible CAD
LV volumes and EF
Evaluate for possible CAD
in patient evaluation.
photon emission computed tomography; other abbreviations as in Tables 3, 5, and 6.
CENTRAL ILLUSTRATION Imaging and Genetic Testing for Patients and Families With Monogenic Cardiac Diseases
Associated With SCD
The ﬁgure presents the role of imaging in patients with monogenic cardiac diseases associated with SCD. Imaging plays an important role in patients who are genotype
positive-phenotype negative, genotype positive-phenotype positive, and those who are genotype negative but phenotype positive. Imaging is essential to establish the
diagnosis, to guide treatment in some patients, to assess response to therapy as well as risk stratiﬁcation. ARVC ¼ arrhythmogenic right ventricular cardiomyopathy;
DCM ¼ dilated cardiomyopathy; HCM ¼ hypertrophic cardiomyopathy; LV ¼ left ventricular; RV ¼ right ventricular; SCD ¼ sudden cardiac death.
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843Regular clinical evaluation with imaging should be
considered for relatives with known mutations
because the disease can present later in life, albeit
there is variable penetrance. Repeat evaluation at
yearly intervals is recommended for ﬁrst-degree rel-
atives with abnormal ﬁndings according to clinical
examination, ECG, or echo/CMR (38).
CONCLUSIONS
Imaging plays an important role in establishing the
diagnosis of many of the monogenic cardiac disor-
ders associated with SCD (Table 6). The correct
diagnosis expectedly leads to the timely initiation oftreatment and affords families the possibility of ge-
netic counseling once the pathogenic mutation in
the proband is determined. In addition, key ﬁndings
noted according to imaging can identify patients
at a high risk for SCD and can be used to inform
the decision for ICD implantation. Imaging has also
been used to screen family members because
abnormalities in cardiac structure and function
may be detected at a stage preceding the develop-
ment of the pathognomonic phenotype (Central
Illustration). Table 7 presents a summary for the
clinical applications of the different imaging mo-
dalities, some of which follow published guidelines
for the role of imaging in the evaluation of patients
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844with cardiomyopathic disorders (5,25). In general,
morphology and function are readily examined by
echocardiography and CMR, whereas computed
tomography and nuclear techniques can be consid-
ered for evaluation of coronary artery disease. In
addition, cardiac computed tomography can be used
for evaluation of cardiac morphology in patients
with suboptimal echocardiographic images andwhere CMR cannot be performed due to the pres-
ence of ICDs or pacemakers.
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